Financial statements Notes to the Company financial statements continued For the year ended 31 December 2016 53.
Long-term financial debts A $500 million with a fair value of $495 million 4.25 per cent.
Eurobond due April 2020 with the rating of BB Ba1.
The proceeds were used to refinance existing debt and to finance part of the cash consideration of West-Ward Columbus acquisition.
Other non-current liabilities Co-development and earnout payment agreement In 2015 the liability mainly relates to the present value of future payments on a co-development and earnout agreement.
As part of this agreement, milestone payments dependent on successful clinical development of defined products are received by the Group.
In return of receiving such milestone payments, the Group has agreed to pay the contracting party a certain percentage of future sales of those products.
As at 31 December 2016 and 31 December 2015, the liability associated with these earnout payments was adjusted to reflect the present value of the expected future cash outflows and the difference is presented as a finance cost income.
During 2016, the total liability was transferred to sister company, however PLC still acts as guarantor for the performance of a number of its affiliates pursuant to various agreements.
Financial policies for risk management and their objectives Currency risk Currency risks as defined by IFRS 7 arise on account of financial instruments being denominated in a currency that is not the functional currency and being of a monetary nature.
The following table illustrates financial assets and liabilities for the Company in different currencies: Liabilities Assets 2016 2015 2016 2015 $m $m $m $m British Pound 1 A sensitivity analysis based on a 10% movement in foreign exchange rates has no material impact on the Company results and Company statement of changes in equity.
Further details on how the Company manages the currency risk are given in Note 30.
Interest rate risk As at 31 December As at 31 December 2016 2015 Fixed rate Floating rate Total Fixed rate Floating rate Total $m $m $m $m $m $m Financial liabilities Interest-bearing loans and borrowings 495 145 640 494 494 Financial assets Cash and cash equivalents 27 27 357 357 An interest rate sensitivity analysis assumes an instantaneous 100 basis point change in interest rates in all currencies from their levels at 31 December 2016, with all other variables held constant.
Based on the composition of the Company debt and cash portfolio as at 31 December 2016, a 1% increase in interest rates would result in an additional interest expense of $1 million being incurred per year 2015: $4 million of interest income incurred.
Hikma Pharmaceuticals PLC 206 198 Hikma Pharmaceuticals plc
